ID: ALA436747

Max Phase: Preclinical

Molecular Formula: C36H41N3O7

Molecular Weight: 627.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)OCc2ccc(-c3ccccc3)cc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C36H41N3O7/c1-5-6-17-29(30(40)32(41)37-24(2)26-13-9-7-10-14-26)38-34(43)46-31-33(42)39(23-36(31,3)4)35(44)45-22-25-18-20-28(21-19-25)27-15-11-8-12-16-27/h7-16,18-21,24,29,31H,5-6,17,22-23H2,1-4H3,(H,37,41)(H,38,43)/t24-,29+,31-/m1/s1

Standard InChI Key:  OJEBRSNLJRTXLH-QGXKGNFASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 627.74

Molecular Weight (Monoisotopic): 627.2945

AlogP: 5.96

#Rotatable Bonds: 12

Polar Surface Area: 131.11

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 7.06

CX LogD: 7.06

Aromatic Rings: 3

Heavy Atoms: 46

QED Weighted: 0.24

Np Likeness Score: -0.16

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature